A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects With Schizophrenia
Sponsor: Alkermes, Inc.
A PHASE3 clinical study on Schizophrenia, this trial is completed. The trial is conducted by Alkermes, Inc. and has accumulated 11 data snapshots since 2016. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Aug 2019 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 6 earlier versions
-
Aug 2018 — Aug 2019 [monthly]
Completed PHASE3
Status: Enrolling By Invitation → Completed
-
Jun 2018 — Aug 2018 [monthly]
Enrolling By Invitation PHASE3
-
Jan 2018 — Jun 2018 [monthly]
Enrolling By Invitation PHASE3
-
Jun 2017 — Jan 2018 [monthly]
Enrolling By Invitation PHASE3
-
Feb 2017 — Jun 2017 [monthly]
Enrolling By Invitation PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Enrolling By Invitation PHASE3
First recorded
Jan 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Alkermes, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Belgrade, Serbia , Burgas, Bulgaria , Chicago, United States , Culver City, United States , Dallas, United States , Dayton, United States , Garden Grove, United States , Kazanlak, Bulgaria , Kharkiv, Ukraine , Kiev, Ukraine and 21 more locations